Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tizanidine HCl
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : National Institutes of Health
Deal Size : $2.5 million
Deal Type : Funding
Details : Proceeds from the financing will be used for the advancement of the company’s tizanidine implant product (DLP-208) for moderate-severe spasticity. DLP-208 can provide sustained therapy for several months, while only requiring a 10-minute procedure in a...
Brand Name : DLP-208
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 16, 2021
Lead Product(s) : Tizanidine HCl
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : National Institutes of Health
Deal Size : $2.5 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?